Introduction. LIM Homeobox 6 (LHX6) encodes a LIM homeodomain transcription factor, contributes to tissue development and morphogenesis, and is mostly expressed in medial ganglionic eminence and odontogenic mesenchyme. However, it has been reported to play a role in cancer progression. This narrative review summarizes literatures that emphasize the molecular regulation of LHX6 in tumorigenesis.
INTRODUCTION

Lim Homeobox 6 (LHX6) is a member of LIM
Homeobox gene family that is located in chromosome 9q33.2. Its regulation is mostly involved in tissue morphogenesis and development [1, 2] . In neurogenesis, LHX6 plays a significant role in the specification and migration of GABAergic cortical interneurons (CIN), specifically parvalbumin-positive (PV + ) and somatostatin-positive (STT + ) interneurons within the neocortex, hippocampus, and medial ganglionic eminence (MGE) [3] [4] [5] [6] . Moreover, in vitro and in vivo studies showed that LHX6 interacts with Lim homeobox 8 (LHX8), SRY-box 2 (SOX2), and Forkhead box 1 (FOXG1) for GABAergic interneuron cell fates, migration, and globus pallidus differentiation via sonic hedgehog (SHH) signaling pathway, where it regulates the formation of CIN progenitor [7] [8] [9] [10] [11] [12] . LHX6 also upregulates Aristaless related homeobox (ARX) and C-X-C chemokine receptor 7 (CXCR7) expression which eventually promote the maturation, migration and laminar positioning of cortical interneurons in MGE [10, 13, 14] . In addition, LHX6 controls numbers and types of interneurons that migrate to certain positions within the cerebral layers [15, 16] .
LHX6 is known to be expressed in the odontogenesis and palatogenesis, where its interaction with β-catenin and lymphoid enhancer binding factor 1 (LEF-1) suppresses the activation of PITX2, which controls dental stem cell proliferation and differentiation [17] [18] [19] [20] [21] [22] [23] . Knockout of LHX6 and LHX8 in the dental mesenchymal region causes specification failure of the molar mesenchyme and upregulation of p57 Kip2 , hindering the growth of molar teeth and palatal shelves [17, 18, 23] . Several studies have reported that LHX6 also plays important roles in tumorigenesis by exerting its tumor suppressing abilities. However, its promoter hypermethylation might cause the downregulation of this gene in certain types of cancer. Therefore, our systematic review aims to provide emerging updates about LHX6 in cancer and its potential role as a tumor suppressor and prognostic biomarker. 
MATERIAL AND METHODS
Literature Search
Inclusion and Exclusion Criteria
The articles from the database with the keywords input were screened and analyzed (n = 15) with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [24] using the following criteria: (1) original articles; (2) accessible papers; (3) published in English language; (4) published within year 2006-2017; (5) in vitro, in vivo, and clinical studies; (6) qualitative and/or quantitative results; (7) studies assessing levels of LHX6 in cancer cells and/or its mechanism as a potential tumor suppressor (Figure 1 ). We excluded conference abstracts, letters, and review articles. EN, MST, and SE independently examined and screened the titles and abstracts of records identified for eligibility. 
Data Extraction
We gathered all of the full-text articles that met the inclusion criteria. The results from 7 research articles that are relevant to this review were extracted and analyzed by EN, MST, GR, and SE. These data were further confirmed by ASL, MPU, and AS. The outcomes of the studies were comprehensively analyzed and discussed.
RESULTS
Study characteristics
Studies that are used in this review are categorised as level IV evidence as they are more involved in analysis of outcomes without involving patients, focusing more on in vitro, in vivo, and clinical studies ( Table 1 ). The studies used in this review have a low to moderate level of certainty.
However, all studies showed consistent results, including promoter hypermethylation and downregulation of LHX6 in various cancer types. Due to the consistency in the results obtained, further research in regards to this topic could be performed. 
In vitro studies
In head and neck squamous cell carcinoma (HNSCC) cell lines, cyclin D1 and cortactin are overexpressed due to the deletion of regions of tumor suppressing chromosome 3p which may cause tumor progression [31] . The breast cancer cell lines, MCF-7 and MDA-MB-231, have been shown to have high tumorigenic potential in the presence of oestrogen [32] . In cervical cancer cell lines, chromosome 3q that was associated with the progression of tumors from high grade CIN to invasive CC was found to be amplified [33] . In lung cancer cell lines, expression of various genes such as LKB1 and TITF1, which affects lung cancer pathogenesis, is abnormal [34] . These results show that the cell lines are suitable for the research on the tumor suppressor ability of LHX6.
In vivo studies
Three in vivo studies were analyzed in our review, including studies using BALB/C-nude mice to investigate LHX6 expression in lung adenocarcinoma [35] and breast cancer [36] .
Clinical studies
Clinical sample characteristics of the total 441 samples are described (Table 2) . Age was known to have a range of 21-82 years. Gender of which clinical samples were obtained were reported in seven studies, dominated by female (72%). Primary tumor sites were mostly from cervical cancer (36%), followed by lung cancer (n = 157, 36%). Breast cancer and HNSCC shared the same amount of samples (n = 32, 7%). From the studies reported, most of the tumors were stage I-II (n = 230, 52%). 
LHX6 expression is downregulated in certain types of cancer
In physiological conditions, LHX6 is widely expressed during odontogenesis and neurogenesis. However, several studies have shown that the expression of LHX6, at both transcriptional and translational levels, is downregulated during lung adenocarcinoma and breast cancer progression [25] [26] [27] . In addition, Jung et al. have shown that, in cervical cancer cells, gene transcription of hLHX6 (Homo sapiens LIM homeobox domain 6) and its isoform, hLHX6.1, were suppressed [28] . Furthermore, Yang et al. reported that LHX6 expression is higher in lymph node-negative patients compared to lymph node-positive patients [25] . Moreover, LHX6 expression in patients with metastatic lung cancer is downregulated [25] . Thus, in lung adenocarcinoma, breast cancer, and cervical cancer, downregulation of LHX6 might possibly contribute to the cancer progression [25] [26] [27] [28] 30] .
LHX6 tumor suppressing ability
Cancer patients with low LHX6 expression were reported to have shorter survival rate compared to individuals that have overexpression of LHX6 [25] . Moreover, decreased LHX6 expression induced an increase in cell viability, colony formation, and growth of cancer cells in vitro [25, 27] . Studies performed using lung (LTEP-a-2, SPC-a-1, 95D and H358) and breast (MCF7 and MDA-MB-231) cancer cell lines showed that LHX6 inhibits cell proliferation [25] [26] [27] . In addition, increased mRNA expressions of LHX6 and hLHX6.1 were observed in lung (95D and H358) and cervical (SiHa) cancer cell lines, thus reduced the tumor cell colony size and number, prevented the colony formation, and decreased the ability of cancer cells to migrate and invade [25, 27, 28] . In vivo studies using nude mice also showed that administration of LHX6-overexpressing cells reduced tumor weight and volume and inhibited metastasis in liver cancer [25] [26] [27] . Hence, LHX6 exerts its tumor suppressive ability in both in vivo and in vitro.
LHX6 is hypermethylated in cancer
The hLHX6 fragments, hLHX6-HMR and differentially methylated 6 (DIME6), are located in between exon 4a and exon 5 of hLHX6 promoter [29] . These fragments are prone to hypermethylation, especially DIME6 [2, 29] . This hypermethylation specifically occurs on the cytosine guanine dinucleotide (CpG) sites of these fragments, in which a methyl group is enzymatically added on the cytosines in the 5' position with respect to the guanine of the CpG site, causing epigenetic alteration [2] . The hypermethylation in the promoter region of the hLHX6 gene might be the cause of its repressed expression [2, 29] .
hLHX6 and LHX6 show little to no hypermethylation in normal cells. However, in early stages of cervical cancer carcinogenesis, the frequency of methylation increases alongside cancer progression [29] . LHX6, hLHX6-HMR, and hLHX6.1 are shown to be either partially methylated or fully methylated in certain types of cancers such as lung, cervical, head, and neck cancer [26] [27] [28] [29] . Liu et al. have shown that in lung cancer, the CpG island is hypermethylated, suggesting that methylation of the CpG island causes the downregulation of LHX6 [27] . The study by Jung et al. further supports this hypothesis by showing that CpG-rich hLHX6.1 promoter hypermethylation occurs in cervical cancer cells. In cervical cancer, transcriptional level of hLHX6.1 is shown to be decreased in cells with hypermethylated hLHX6.1 promoter [28] . Therefore, we propose that downregulation of hLHX6 expression in cancer cells is caused by hypermethylation of the CpG island of hLHX6 promoter.
Molecular mechanisms of LHX6 regulation in cancer
Wnt/β-catenin is involved in progression of certain types of cancer such as breast cancer and lung cancer. The important regulator of this canonical pathway, β-catenin, is involved in a series of events which further activate the downstream genes involved in cell proliferation, cell migration, and metastasis. LHX6 reduces the expression of β-catenin and therefore disrupts the Wnt/β-catenin signaling cascade [25, 27] . LHX6 further exerts its tumor suppressing abilities by upregulating p53, a proapoptotic gene which is involved in several pathways that promote or inhibit several genes ( Figure 2 ) [25, 27] . These genes promote apoptosis, DNA repair and inhibit cell proliferation, growth, metabolic transformation, and migration [25, 27] . Moreover, LHX6 inhibits CD44 and MMP7 which are involved in cell migration and metastasis [25, 27] . 140 
LHX6 expression in clinical cancer samples
LHX6 expression was found to be downregulated in clinical cancer samples. Promoter hypermethylation of hLHX6.1 was observed as the normal cervical cancer cells progress into cancer cells [28] . Interestingly, hLHX6 promoters did not show any hypermethylation in the tissue sample [28] . Jung et al. also found the specific CpG-island hypermethylation site in LHX6, hLHX6-HMR [29] . The analysis showed that hLHX6-HMR hypermethylation was also evident during carcinogenesis [29] . Moreover, the hypermethylation of hLHX6-HMR can be observed from the early stages of cervical cancer tumorigenesis [29] . In addition, the age of patients was correlated with the hypermethylation of hLHX6-HMR, which might suggest that tumor cells progress as age increases [29] .
In lung cancer tissues, LHX6 expression was downregulated in comparison to healthy lung tissues [25] [26] [27] . Furthermore, LHX6 is hypermethylated in more than half of the clinical samples [27] . In addition, LHX6 was observed to be specific to lung adenocarcinoma but not in squamous cell carcinoma [25] . LHX6 also has a strong relation to cancer stage, size, and lymph node status in lung adenocarcinoma [25] . When LHX6 expression was highly expressed in a lymph-node negative and/or lung adenocarcinoma cancer patient, it may increase the overall survival of the patients [25] . In head and neck cancer, Estécio et al. showed a high amount of CpG-rich hypermethylation in DIME-6 [2] . DIME-6 is correlated to promoter region of an mRNA that possibly represents a short isoform of LHX6. Therefore, if DIME-6 is hypermethylated, the short isoform of LHX6 is less likely to be present [2] . The downregulation of LHX6 is involved in non-small-cell lung cancer (NSCLC) development [30] . LHX6 is also found to be regulated by miR-214, one of the causes of erlotinib resistance in NSCLC [30] . However, when LHX6 is overexpressed, miR-214 will have decreased expression which results in reversal of erlotinib resistance [30] .
Taken together, downregulated LHX6 might be present in specific cancer tissues due to its promoter methylation. The level of hypermethylation is positively correlated with cancer progression; this phenomenon might have potential as a prognostic biomarker.
Limitations and Future Research Suggestions
The included studies involve limited types of cancers. However, some cancer cell lines have shown possibility of LHX6 being involved in the tumorigenesis, such as colon cancer and leukemia [2] . Hence, LHX6 activity should be further observed in the clinical samples of these types of cancer. Another limitation is the lack of specific molecular pathways that affect the upstream and downstream of LHX6 in its tumor suppressor activity. Hypermethylation of hLHX6.1 has a possibility of going through epigenetic and genetic regulations that require further research [28] .
CONCLUSION
LHX6 plays a significant role in the inhibition of tumor growth and cancer progression through the regulation of pleiotropic mechanisms in certain cancer cells, specifically lung, breast and cervical cancer. Furthermore, downregulation of LHX6 expression due to promoter hypermethylation might lead to accelerated tumor progression and impaired tumor suppressive abilities. Future studies are necessary to investigate the potential of LHX6 as a novel cancer biomarker as well as its therapeutic implications by using clinical samples.
